Aker Biomarine ASA
OSE:AKBM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
20.5799
59.5148
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AKBM stock under the Base Case scenario is 68.84 NOK. Compared to the current market price of 51.7 NOK, Aker Biomarine ASA is Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aker Biomarine ASA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AKBM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aker Biomarine ASA
Balance Sheet Decomposition
Aker Biomarine ASA
Current Assets | 172.5m |
Cash & Short-Term Investments | 16.3m |
Receivables | 45.3m |
Other Current Assets | 110.9m |
Non-Current Assets | 637.6m |
PP&E | 102.2m |
Intangibles | 139.7m |
Other Non-Current Assets | 395.7m |
Current Liabilities | 41.1m |
Accounts Payable | 23.6m |
Other Current Liabilities | 17.5m |
Non-Current Liabilities | 413.5m |
Long-Term Debt | 164.7m |
Other Non-Current Liabilities | 248.8m |
Earnings Waterfall
Aker Biomarine ASA
Revenue
|
305m
USD
|
Cost of Revenue
|
-204.2m
USD
|
Gross Profit
|
100.8m
USD
|
Operating Expenses
|
-97.5m
USD
|
Operating Income
|
3.3m
USD
|
Other Expenses
|
-3.5m
USD
|
Net Income
|
-200k
USD
|
Free Cash Flow Analysis
Aker Biomarine ASA
USD | |
Free Cash Flow | USD |
Aker BioMarine reported $94 million in revenue for Q2, a 6% increase year-over-year, with an EBITDA of $29 million, up 35%. The sale of its Feed Ingredients business for $590 million will finalize in Q3, enabling an extraordinary dividend of NOK 35-45 per share. The Human Health Ingredients segment grew by 22%, with robust development expected to continue. However, Consumer Health Products faced inventory adjustments, impacting short-term performance. Aker BioMarine plans to streamline overhead costs and optimize their remaining human health and nutrition-focused business, aiming to maximize shareholder value by growing EBITDA and seeking optimal transaction timings.
What is Earnings Call?
AKBM Profitability Score
Profitability Due Diligence
Aker Biomarine ASA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Aker Biomarine ASA's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
AKBM Solvency Score
Solvency Due Diligence
Aker Biomarine ASA's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Aker Biomarine ASA's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AKBM Price Targets Summary
Aker Biomarine ASA
According to Wall Street analysts, the average 1-year price target for AKBM is 78.03 NOK with a low forecast of 73.73 NOK and a high forecast of 84 NOK.
Dividends
Current shareholder yield for AKBM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aker BioMarine AS operates as a biotech innovator and Antarctic krill-harvesting company which develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company is headquartered in Lysaker, Akershus. The company went IPO on 2020-07-06. The company consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine’s focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.
Contact
IPO
Employees
Officers
The intrinsic value of one AKBM stock under the Base Case scenario is 68.84 NOK.
Compared to the current market price of 51.7 NOK, Aker Biomarine ASA is Undervalued by 25%.